Single-cell RNA transcriptomic and plasma Lipidomic reveal the potential mechanisms of a Methotrexate-based therapy against Rheumatoid Arthritis.

[1]  Qiang Xu,et al.  New opportunities and challenges of natural products research: When target identification meets single-cell multiomics , 2022, Acta pharmaceutica Sinica. B.

[2]  U. Göransson,et al.  Where traditional Chinese medicine meets Western medicine in the prevention of rheumatoid arthritis , 2022, Journal of internal medicine.

[3]  Runyue Huang,et al.  Chinese Herbal Formula Huayu-Qiangshen-Tongbi Decoction Attenuates Rheumatoid Arthritis through Upregulating miR-125b to Suppress NF-κB-Induced Inflammation by Targeting CK2 , 2022, Journal of immunology research.

[4]  M. Rattray,et al.  Chronic inflammatory arthritis drives systemic changes in circadian energy metabolism , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[5]  S. Kwon,et al.  Lipidome profile predictive of disease evolution and activity in rheumatoid arthritis , 2022, Experimental & Molecular Medicine.

[6]  Rebekah L. Gundry,et al.  Plasma Metabolome Normalization in Rheumatoid Arthritis Following Initiation of Methotrexate and the Identification of Metabolic Biomarkers of Efficacy , 2021, Metabolites.

[7]  Runyue Huang,et al.  The Effect of Chinese Medicine Compound in the Treatment of Rheumatoid Arthritis on the Level of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibodies: A Systematic Review and Meta-Analysis , 2021, Frontiers in Pharmacology.

[8]  Jin Li,et al.  Traditional herbal medicine: Therapeutic potential in rheumatoid arthritis. , 2021, Journal of ethnopharmacology.

[9]  Lara A. Kahale,et al.  2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2021, Arthritis & rheumatology.

[10]  W. Liu,et al.  Traditional Chinese Medicine Qingre Huoxue Treatment vs. the Combination of Methotrexate and Hydroxychloroquine for Active Rheumatoid Arthritis: A Multicenter, Double-Blind, Randomized Controlled Trial , 2021, Frontiers in Pharmacology.

[11]  P. Zhou,et al.  Identification of Tumor Necrosis Factor-Alpha (TNF-α) Inhibitor in Rheumatoid Arthritis Using Network Pharmacology and Molecular Docking , 2021, Frontiers in Pharmacology.

[12]  Raphael Gottardo,et al.  Integrated analysis of multimodal single-cell data , 2020, Cell.

[13]  Runyue Huang,et al.  Chinese Herbal Formula Huayu-Qiangshen-Tongbi Decoction Compared With Leflunomide in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis: An Open-Label, Randomized, Controlled, Pilot Study , 2020, Frontiers in Medicine.

[14]  A. Barton,et al.  Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics , 2020, Scientific Reports.

[15]  Bisera Stepanovska,et al.  Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases. , 2020, Pharmacological research.

[16]  Tsutomu Takeuchi,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update , 2020, Annals of the Rheumatic Diseases.

[17]  Jin-jian Lu,et al.  Deciphering the Pharmacological Mechanisms of the Huayu-Qiangshen-Tongbi Formula Through Integrating Network Pharmacology and In Vitro Pharmacological Investigation , 2019, Front. Pharmacol..

[18]  P. Calder,et al.  Plasma Levels of Eicosapentaenoic Acid Are Associated with Anti-TNF Responsiveness in Rheumatoid Arthritis and Inhibit the Etanercept-driven Rise in Th17 Cell Differentiation in Vitro , 2017, The Journal of Rheumatology.

[19]  Xianlin Han,et al.  Lipidomics for studying metabolism , 2016, Nature Reviews Endocrinology.

[20]  T. Hankemeier,et al.  Differences between serum polar lipid profiles of male and female rheumatoid arthritis patients in response to glucocorticoid treatment , 2016, Inflammopharmacology.

[21]  C. Bombardier,et al.  Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis. , 2016, The Cochrane database of systematic reviews.

[22]  D. Boyle,et al.  Metabolomic profiling predicts outcome of rituximab therapy in rheumatoid arthritis , 2016, RMD Open.

[23]  C. Bombardier,et al.  Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis , 2016, British Medical Journal.

[24]  P. Emery,et al.  The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results From a Multinational, Phase IIb, Randomized, Double‐Blind, Placebo/Active‐Controlled, Dose‐Ranging Study , 2015, Arthritis & rheumatology.

[25]  M. Milad,et al.  Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib†, ‡ , 2015, Arthritis & rheumatology.

[26]  Sarah Spiegel,et al.  Sphingolipid metabolites in inflammatory disease , 2014, Nature.

[27]  H. Paulus,et al.  Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. , 2013, Arthritis and rheumatism.

[28]  J. Kay,et al.  ACR/EULAR 2010 rheumatoid arthritis classification criteria. , 2012, Rheumatology.

[29]  C. Bombardier,et al.  Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis , 2008, Annals of the rheumatic diseases.

[30]  Paul Bird,et al.  OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. , 2003, The Journal of rheumatology.

[31]  N. Miyasaka,et al.  Ceramide, a mediator of interleukin 1, tumour necrosis factor α, as well as Fas receptor signalling, induces apoptosis of rheumatoid arthritis synovial cells , 1998, Annals of the rheumatic diseases.

[32]  J J Anderson,et al.  American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[33]  A. Gomez-Muñoz,et al.  Control of inflammatory responses by ceramide, sphingosine 1-phosphate and ceramide 1-phosphate. , 2016, Progress in lipid research.